# US 9,751,935 B2 · Anti-serum albumin binding variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,751,935 B2
- Document ID: US9751935B2
- Status: Granted
- Kind: B2
- Application number: 14/862,818
- Filed: 2015-09-23
- Published: 2016-03-17
- Granted: 2017-09-05
- Earliest claimed: 2009-02-19
- Assignees: Glaxo Group Limited
- Applicants: Glaxo Group Limited
- Inventors: Elena De Angelis; Carolyn Enever; Haiqun Liu; Oliver Schon
- Web page: https://patentgrep.com/patent/US9751935B2

## CPC

- C07K 16/18: against material from animals or humans
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C07K 14/56: IFN-alpha
- C07K 14/57563: {Vasoactive intestinal peptide [VIP]; Related peptides}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.

## Claims

### Claim 1

A nucleic acid comprising a nucleotide sequence encoding an anti-serum albumin immunoglobulin single variable domain comprising the amino acid sequence of SEQ ID NO: 412 (DOM7h-14-10 R108C).

### Claim 2 (depends on 1)

A vector comprising the nucleic acid of claim 1.

### Claim 3 (depends on 2)

An isolated host cell comprising the vector of claim 2.

### Claim 4

A nucleic acid comprising a nucleic acid comprising a nucleotide sequence encoding an anti-serum albumin immunoglobulin single variable domain, said nucleic acid comprising the nucleotide sequence of SEQ ID NO: 413 (DOM7h-14-10 R108C).

### Claim 5 (depends on 4)

A vector comprising the nucleic acid of claim 4.

### Claim 6 (depends on 5)

An isolated host cell comprising the vector of claim 5.